Key Details
Price
$33.85PE Ratio
2.98Annual ROE
-36.83%Beta
1.57Events Calendar
Next earnings date:
Feb 14, 2025Recent quarterly earnings:
Oct 31, 2024Recent annual earnings:
Feb 15, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
If approved, AGIO's Pyrukynd will be the first oral therapy for all thalassemia subtypes. A final decision is expected by Sep. 7.
The fall in AGIO stock comes after reports of an unexpected side effect linked to its sole-marketed drug Pyrukynd in thalassemia patients.
This Industry Outlook article has featured ResMed, Haemonetics, Phibro, and Agios.
The increasing need for medical procedures and efforts to reduce costs are expected to benefit the Zacks Medical-Products industry. Companies like RMD, HAE, PAHC, and AGIO are likely to take advantage of these positive trends.
An ongoing rise in demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. RMD, HAE, PAHC and AGIO are well-poised to gain from the favorable factors.
Here is how Agios Pharmaceuticals (AGIO) and Twist Bioscience (TWST) have performed compared to their sector so far this year.
Agios' third-quarter 2024 earnings miss estimates while revenues match the same. Shares fall.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q3 2024 Earnings Conference Call October 31, 2024 8:00 AM ET Company Participants Chris Taylor - Vice President, Investor Relations and Corporate Communications Brian Goff - Chief Executive Officer Sarah Gheuens - Chief Medical Officer and Head, R&D Tsveta Milanova - Chief Commercial Officer Cecilia Jones - Chief Financial Officer Conference Call Participants Greg Harrison - Scotiabank Alex Nackenoff - Raymond James Greg Renza - RBC Capital Markets Eric Schmidt - Cantor Fitzgerald Chris Raymond - Piper Sandler Tessa Romero - JPMorgan Divya Rao - TD Cowen Alec Stranahan - Bank of America Lydia Erdman - Goldman Sachs Andrew Berens - Leerink Partners Operator Good morning, and welcome to Agios' Third Quarter 2024 Conference Call. [Operator Instructions] Please be advised that today's call is being recorded at Agios' request.
Agios Pharmaceuticals (AGIO) came out with quarterly earnings of $4.20 per share, missing the Zacks Consensus Estimate of $16.69 per share. This compares to loss of $1.64 per share a year ago.
– Completed Enrollment of the Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease; Topline Data from 52-Week Study Expected in Late 2025 – – Received $1.1 Billion in Payments from Royalty Pharma and Servier, Following FDA Approval of Vorasidenib – – Commenced Enrollment of the Phase 2b Study of Tebapivat in Lower-Risk Myelodysplastic Syndromes (LR-MDS); Granted FDA Orphan Drug Designation for Treatment of MDS – – PYRUKYND® (Mitapivat) Net Revenue of $9.0 Million in Q3; Cash, Cash Equivalents and Marketable Securities of $1.7 Billion as of September 30, 2024 – CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today reported business highlights and financial results for the third quarter ended September 30, 2024.
FAQ
- What is the ticker symbol for Agios Pharmaceuticals?
- Does Agios Pharmaceuticals pay dividends?
- What sector is Agios Pharmaceuticals in?
- What industry is Agios Pharmaceuticals in?
- What country is Agios Pharmaceuticals based in?
- When did Agios Pharmaceuticals go public?
- Is Agios Pharmaceuticals in the S&P 500?
- Is Agios Pharmaceuticals in the NASDAQ 100?
- Is Agios Pharmaceuticals in the Dow Jones?
- When was Agios Pharmaceuticals's last earnings report?
- When does Agios Pharmaceuticals report earnings?
- Should I buy Agios Pharmaceuticals stock now?